Publications
- Immunotherapy in squamous NSCLC - nivolumab clinical data, our experiences with nivolumab treatment2018 | Faculty of Medicine in Pilsen
- Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment2016 | Faculty of Medicine in Pilsen
- Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report2014 | Faculty of Medicine in Pilsen
- Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine, Third Faculty of Medicine
- Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab plus Chemotherapy2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Czech patient with lung adenocarcinoma with the BRAF V600E mutation succesfully treated with dabrafenib plus trametinib2021 | Faculty of Medicine in Pilsen, Central Library of Charles University
- Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Adjuvant durvalumab after successful concomitant chemoradiotherapy of non-small cell lung cancer treatment2021 | Faculty of Medicine in Pilsen
- Immunotherapy of lung cancer and basic principle of immune system acting2021 | Faculty of Medicine in Pilsen
- Biologically targeted treatment in non-small cell lung cancer or "do we always have mutations and PD-L1 examined?" - case report2021 | Faculty of Medicine in Pilsen
Loading network view...